New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 26, 2012
10:23 EDTBSX, STJ, MDTBoston Scientific rises after Citi sees Durata coming off market
Boston Scientific (BSX) is climbing after Citigroup analyst Matthew Dodds upgraded the stock to Buy from Neutral in a note to investors earlier today. Durata cables made by St. Jude (STJ), a Boston Scientific competitor, will likely be taken off the market within six months, Dodds believes. Earlier this year a study found that Durata cables can fray when they rub against another object. Boston Scientific will benefit significantly from the withdrawal of St. Jude's cables, which are used to connect defibrillators to the heart, Dodds wrote. If Durata cables are removed from the market, Boston Scientific would obtain 41% of the $338M in revenue that St. Jude would lose, the analyst predicted. Medtronic (MDT) will garner 29% of St. Jude's lost sales, adds Dodds. The analyst increased his price target on Boston Scientific to $7.30 from $5.30. In mid-morning trading, Boston Scientific climbed 19c, or 3.40%, to $5.78, while St. Jude fell 35c, or 1.09%, to $31.68.
News For BSX;STJ;MDT From The Last 14 Days
Check below for free stories on BSX;STJ;MDT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
August 31, 2014
12:50 EDTMDTEuropean Society of Cardiology to hold a conference
Subscribe for More Information
August 29, 2014
17:06 EDTBSXBoston Scientific reports results from multinational stent study
A Boston Scientific prospective, multinational study on stent removability and preliminary long term stricture resolution of benign biliary strictures has been published in the August issue of the peer-reviewed journal, Gastroenterology. The multinational study is being conducted in 11 countries and five continents, and examines removal of fully covered self-expanding metal stents after extended indwell. The 187-patient study was designed to evaluate the ability to remove the Fully Covered WallFlex Biliary RX Stent after extended indwell and to determine treatment success of biliary obstructions resulting from benign biliary strictures. Data highlights: The WallFlex Biliary RX Stents were successfully removed by endoscopy from all 155 patients in whom this procedure was attempted. Stricture resolution without the need to restent at the time of stent removal was successful in approximately 75% of patients. Approximately 85% of these patients remained stricture-free after a mean follow-up of 20 months. The study results demonstrate that FCSEMS are an effective treatment alternative to plastic stents, and may significantly reduce the need for multiple sequential Endoscopic Retrograde Cholangiopancreatogram stent exchanges and the associated complications and costs.
August 28, 2014
17:42 EDTMDT, STJ, BSXJ&J begins sales process for its medical device unit Cordis, WSJ says
Subscribe for More Information
09:05 EDTMDTMedtronic receives clearance for Shilla Growth Guidance System
Subscribe for More Information
August 27, 2014
11:41 EDTMDTMedtronic management to meet with Jefferies
Subscribe for More Information
10:05 EDTMDTMedtronic announces first implants in AdaptResponse CRT clinical trial
Medtronic announced the first implants in a clinical trial that will compare patient and healthcare system outcomes in heart failure patients who have cardiac resynchronization therapy devices with the AdaptivCRT feature enabled versus patients receiving standard CRT. The AdaptResponse trial will assess the superiority of the AdaptivCRT algorithm, which preserves normal heart rhythms and automatically adjusts to patients' needs to customize therapy. It is expected to enroll approximately 3K patients worldwide. The primary endpoint of the AdaptResponse trial is a combination of all-cause mortality and the rate of medical intervention for worsening heart failure. The trial also will examine the incidence of atrial fibrillation in enrolled patients. Other secondary endpoints will assess patient quality of life measures as well as cost-effectiveness of CRT devices with the AdaptivCRT feature relative to standard CRT. Patients will receive a CRT-pacemaker or CRT-defibrillator equipped with the AdaptivCRT algorithm, and will be randomized 1:1 to either treatment or control groups. Patients will be followed at three and six months after randomization, and then every six months until trial closure.
05:40 EDTMDTMedtronic sees impact of NGC Medical acquisition neutral to FY15 earnings
Subscribe for More Information
August 26, 2014
19:33 EDTMDTCovidien shareholder sues to block sale to Medtronic, Bloomberg reports
Subscribe for More Information
16:29 EDTSTJSt. Jude Medical resolves FDA warning letter for Plano facility
Subscribe for More Information
05:54 EDTMDTMedtronic acquires Sapiens SBS for $200M
Subscribe for More Information
August 25, 2014
11:09 EDTBSXFDA confirms third Watchman panel for Boston Scientific, says Wells Fargo
Subscribe for More Information
10:03 EDTMDTMedtronic announces FDA approval of Viva CRT-P for heart failure or AV block
Subscribe for More Information
August 20, 2014
08:47 EDTMDTMedtronic valuation attractive, says Morgan Stanley
Morgan Stanley said Medtronic's (MDT) valuation is attractive given pipeline execution, margin growth and shareholder returns, and expectations for the Covidien (COV) deal to go through. Shares are Overweight rated
07:18 EDTMDTMedtronic shares have upside with or without deal, says Deutsche Bank
Deutsche Bank sees limited downside risk and significant upside potential for shares of Medtronic (MDT), with or without the pending Covidien (COV) acquisition. Deutsche says the Q1 results show improving trends and it keeps a Buy rating on Medtronic with an $85 price target.
August 19, 2014
08:40 EDTMDTMedtronic sees FY15 gross margin of 74.5%-75%, with Q2 on lower end of range
Subscribe for More Information
08:25 EDTMDTMedtronic: Negative factors in Spine segment in Q1 werre temporary
Subscribe for More Information
08:22 EDTMDTMedtronic: We will continue to pay significant US taxes following Covidien deal
Subscribe for More Information
07:19 EDTMDTMedtronic backs FY15 EPS view of $4.00-$4.10, consensus $4.04
Subscribe for More Information
07:17 EDTMDTMedtronic reports Q1 EPS 93c, consensus 92c
Reports Q1 revenue $4.27B, consensus $4.25B.
05:14 EDTBSXBoston Scientific, ASAHI INTECC announce joint development programs
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use